Pfizer Inc (PFE MU) stock market data APIs
€21.9185
0.07(0.3%)
as of December 12, 2025
Try our APIs with
free plan!
Pfizer Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for PFE.MU.
Prev. Close
21.9185
Open
21.9546
High
21.9831
Low
21.8815
52 wk Range
17.8665-24.61
Market Cap
262 316 M
Dividends (Yield)
0.0341
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pfizer Inc data using free add-ons & libraries
Get Pfizer Inc Fundamental Data
Pfizer Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pfizer Inc News
New
Pfizer Declares First-Quarter 2026 Dividend
Board of Directors approves quarterly cash dividend of $0.43 per share NEW YORK, December 12, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0....
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
Shares of Eli Lilly LLY rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key se...
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
This article first appeared on GuruFocus. Investors watching the global biotech race may be sensing a shift after Moderna (NASDAQ:MRNA) co-founder and chairman Noubar Afeyan suggested the US could be...
CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?
Shares of CorMedix CRMD have witnessed a strong surge so far this year, primarily driven by the continued strong uptake of the company’s lead marketed therapy, DefenCath (Taurolidine + Heparin). The...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
